1. A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy. Issue 1 (December 2015) Authors: Millns, Helen; Bergemann, Rito; Ackermann, Elizabeth; Monia, Brett; Lukas, Mary Journal: Orphanet journal of rare diseases Issue: Volume 9:Issue 1(2014) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The ISIS-TTRRx-CS2 phase 3 study in patients with familial amyloid polyneuropathy: Baseline results of the first 100 patients for the NIS, NIS+7 and mNIS+7 using different methods of scoring: identification of consistencies and key differences. Issue 1 (December 2015) Authors: Bergemann, Rito; Ackermann, Elizabeth; Monia, Brett; Shenker, Andrew; Dyck, Peter Journal: Orphanet journal of rare diseases Issue: Volume 9:Issue 1(2014) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The transthyretin amyloidoses: advances in therapy. Issue 1078 (5th June 2015) Authors: Dubrey, Simon; Ackermann, Elizabeth; Gillmore, Julian Journal: Postgraduate medical journal Issue: Volume 91:Issue 1078(2015) Page Start: 439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗